

William T Abraham

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9949656/publications.pdf>

Version: 2024-02-01

191
papers

15,051
citations

31976

53
h-index

19749

117
g-index

191
all docs

191
docs citations

191
times ranked

10901
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcatheter Mitral-Valve Repair in Patients with Heart Failure. <i>New England Journal of Medicine</i> , 2018, 379, 2307-2318.	27.0	2,079
2	Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. <i>Lancet</i> , The, 2011, 377, 658-666.	13.7	1,345
3	Randomized Trial of Cardiac Resynchronization in Mildly Symptomatic Heart Failure Patients and in Asymptomatic Patients With Left Ventricular Dysfunction and Previous Heart Failure Symptoms. <i>Journal of the American College of Cardiology</i> , 2008, 52, 1834-1843.	2.8	1,060
4	In-Hospital Mortality in Patients With Acute Decompensated Heart Failure Requiring Intravenous Vasoactive Medications. <i>Journal of the American College of Cardiology</i> , 2005, 46, 57-64.	2.8	712
5	Predictors of In-Hospital Mortality in Patients Hospitalized for Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 52, 347-356.	2.8	506
6	Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. <i>Lancet</i> , The, 2016, 387, 453-461.	13.7	478
7	Effects of Cardiac Resynchronization on Disease Progression in Patients With Left Ventricular Systolic Dysfunction, an Indication for an Implantable Cardioverter-Defibrillator, and Mildly Symptomatic Chronic Heart Failure. <i>Circulation</i> , 2004, 110, 2864-2868.	1.6	477
8	Wireless Pulmonary Artery Pressure Monitoring Guides Management to Reduce Decompensation in Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 935-944.	3.9	360
9	Cardiac Resynchronization Therapy for Heart Failure. <i>Circulation</i> , 2003, 108, 2596-2603.	1.6	293
10	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 1956-1964.	27.0	257
11	Sleep disordered breathing and post-discharge mortality in patients with acute heart failure. <i>European Heart Journal</i> , 2015, 36, 1463-1469.	2.2	215
12	Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2015, 3, 487-496.	4.1	204
13	Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. <i>New England Journal of Medicine</i> , 2016, 374, 1521-1532.	27.0	204
14	Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1875-1886.	2.8	198
15	Intrathoracic Impedance vs Daily Weight Monitoring for Predicting Worsening Heart Failure Events: Results of the Fluid Accumulation Status Trial (FAST). <i>Congestive Heart Failure</i> , 2011, 17, 51-55.	2.0	185
16	Wearable Cardioverter-Defibrillator Use in Patients Perceived to Be at High Risk Early Post-Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2013, 62, 2000-2007.	2.8	170
17	Differential Impact of Heart Failure With Reduced Ejection Fraction on Men and Women. <i>Journal of the American College of Cardiology</i> , 2019, 73, 29-40.	2.8	168
18	Echocardiographic Outcomes After Transcatheter Leaflet Approximation in Patients With Secondary Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2969-2979.	2.8	161

#	ARTICLE	IF	CITATIONS
19	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. <i>JACC: Heart Failure</i> , 2018, 6, 874-883.	4.1	159
20	CHAMPION [®] — Trial Rationale and Design: The Long-Term Safety and Clinical Efficacy of a Wireless Pulmonary Artery Pressure Monitoring System. <i>Journal of Cardiac Failure</i> , 2011, 17, 3-10.	1.7	143
21	Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. <i>Lancet</i> , The, 2016, 388, 974-982.	13.7	142
22	Lower Rates of Heart Failure and All-Cause Hospitalizations During Pulmonary Artery Pressure-Guided Therapy for Ambulatory Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006863.	3.9	125
23	Baroreflex Activation Therapy in Patients With Heart Failure With Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1-13.	2.8	121
24	Mechanisms and Clinical Consequences of Untreated Central Sleep Apnea in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2015, 65, 72-84.	2.8	120
25	Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor. <i>Circulation</i> , 2017, 135, 1509-1517.	1.6	117
26	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	2.2	117
27	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea. <i>JACC: Heart Failure</i> , 2015, 3, 360-369.	4.1	114
28	Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2490-2500.	2.8	114
29	3-Year Outcomes of Transcatheter Mitral Valve Repair in Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1029-1040.	2.8	113
30	Interventions Linked to Decreased Heart Failure Hospitalizations During Ambulatory Pulmonary Artery Pressure Monitoring. <i>JACC: Heart Failure</i> , 2016, 4, 333-344.	4.1	112
31	MG53-mediated cell membrane repair protects against acute kidney injury. <i>Science Translational Medicine</i> , 2015, 7, 279ra36.	12.4	103
32	Implantable Hemodynamic Monitoring for Heart Failure Patients. <i>Journal of the American College of Cardiology</i> , 2017, 70, 389-398.	2.8	96
33	Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. <i>European Journal of Heart Failure</i> , 2018, 20, 888-895.	7.1	93
34	Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2428-2445.	2.8	88
35	Evaluation of remote dielectric sensing (ReDS) technology-guided therapy for decreasing heart failure re-hospitalizations. <i>International Journal of Cardiology</i> , 2017, 240, 279-284.	1.7	87
36	Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2015, 17, 1066-1074.	7.1	85

#	ARTICLE	IF	CITATIONS
37	The prevalence and importance of frailty in heart failure with reduced ejection fraction—An analysis of <sc>PARADIGM-HF</sc> and <sc>ATMOSPHERE</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 2123-2133.	7.1	85
38	Cardiovascular Outcomes Assessment of the MitraClip in Patients with Heart Failure and Secondary Mitral Regurgitation: Design and rationale of the COAPT trial. <i>American Heart Journal</i> , 2018, 205, 1-11.	2.7	84
39	The interaction of sex, height, and QRS duration on the effects of cardiac resynchronization therapy on morbidity and mortality: an individual-patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 780-791.	7.1	81
40	Interatrial Shunting for Heart Failure. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2300-2310.	2.9	80
41	Intracardiac Pressures Measured Using an Implantable Hemodynamic Monitor. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	79
42	Pulmonary Artery Pressure-Guided Heart Failure Management Reduces 30-Day Readmissions. <i>Circulation: Heart Failure</i> , 2016, 9, .	3.9	76
43	Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient-level database analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 1803-1813.	7.1	75
44	Rationale and Design of the Left Atrial Pressure Monitoring to Optimize Heart Failure Therapy Study (LAPTOP-HF). <i>Journal of Cardiac Failure</i> , 2015, 21, 479-488.	1.7	69
45	Relationship Between Residual Mitral Regurgitation and Clinical and Quality-of-Life Outcomes After Transcatheter and Medical Treatments in Heart Failure. <i>Circulation</i> , 2021, 144, 426-437.	1.6	68
46	The effect of QRS duration on cardiac resynchronization therapy in patients with a narrow QRS complex: a subgroup analysis of the EchoCRT trial. <i>European Heart Journal</i> , 2015, 36, 1983-1989.	2.2	65
47	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2020, 41, 2109-2117.	2.2	65
48	Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1746-1754.	7.1	64
49	Income Inequality and Outcomes in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 336-346.	4.1	63
50	Impact of Tricuspid Regurgitation on Clinical Outcomes. <i>Journal of the American College of Cardiology</i> , 2020, 76, 1305-1314.	2.8	63
51	Prognostic Models Derived in PARADIGM-HF and Validated in ATMOSPHERE and the Swedish Heart Failure Registry to Predict Mortality and Morbidity in Chronic Heart Failure. <i>JAMA Cardiology</i> , 2020, 5, 432.	6.1	59
52	Devices in the management of advanced, chronic heart failure. <i>Nature Reviews Cardiology</i> , 2013, 10, 98-110.	13.7	56
53	Pulmonary hypertension related to left heart disease: Insight from a wireless implantable hemodynamic monitor. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 329-337.	0.6	56
54	Combinatorial Pharmacogenetic Interactions of Bucindolol and β_1 , β_2 Adrenergic Receptor Polymorphisms. <i>PLoS ONE</i> , 2012, 7, e44324.	2.5	55

#	ARTICLE	IF	CITATIONS
55	Percutaneous Ventricular Restoration Using the Parachute Device in Patients With Ischemic Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 752-758.	3.9	54
56	Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	53
57	Device Therapy in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 931-956.	2.8	50
58	Association of Effective Regurgitation Orifice Area to Left Ventricular End-Diastolic Volume Ratio With Transcatheter Mitral Valve Repair Outcomes. <i>JAMA Cardiology</i> , 2021, 6, 427.	6.1	49
59	Center of excellence for mobile sensor data-to-knowledge (MD2K). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2015, 22, 1137-1142.	4.4	48
60	Remote haemodynamic-guided care for patients with chronic heart failure: a meta-analysis of completed trials. <i>European Journal of Heart Failure</i> , 2017, 19, 426-433.	7.1	46
61	Burden of atrial fibrillation and poor rate control detected by continuous monitoring and the risk for heart failure hospitalization. <i>American Heart Journal</i> , 2012, 164, 616-624.	2.7	45
62	Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta 1 389 Arg/Gly Adrenergic Receptor Polymorphism. <i>JACC: Heart Failure</i> , 2013, 1, 338-344.	4.1	43
63	Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months' experience with the remede [®] System. <i>European Journal of Heart Failure</i> , 2016, 18, 1386-1393.	7.1	43
64	Association of persistent or worsened echocardiographic dyssynchrony with unfavourable clinical outcomes in heart failure patients with narrow QRS width: a subgroup analysis of the EchoCRT trial. <i>European Heart Journal</i> , 2016, 37, 49-59.	2.2	43
65	The clinical characteristics of lower extremity lymphedema in 440 patients. <i>Journal of Vascular Surgery: Venous and Lymphatic Disorders</i> , 2020, 8, 851-859.	1.6	43
66	Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF). <i>American Heart Journal</i> , 2019, 214, 18-27.	2.7	41
67	Improving Heart Failure Therapeutics Development in the United States. <i>Journal of the American College of Cardiology</i> , 2018, 71, 443-453.	2.8	40
68	Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea. <i>Sleep</i> , 2019, 42, .	1.1	40
69	Similar hemodynamic decongestion with vasodilators and inotropes: systematic review, meta-analysis, and meta-regression of 35 studies on acute heart failure. <i>Clinical Research in Cardiology</i> , 2016, 105, 971-980.	3.3	39
70	Implications of Atrial Fibrillation on the Mechanisms of Mitral Regurgitation and Response to MitraClip in the COAPT Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010300.	3.9	39
71	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation in Patients With Moderately Reduced Left Ventricular Ejection Fraction and a Narrow QRS Duration: Study Rationale and Design. <i>Journal of Cardiac Failure</i> , 2015, 21, 16-23.	1.7	38
72	Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas. <i>European Journal of Heart Failure</i> , 2019, 21, 577-587.	7.1	38

#	ARTICLE	IF	CITATIONS
73	Right Ventricularâ€Pulmonary Arterial Coupling in Patients With HF Secondary MR. JACC: Cardiovascular Interventions, 2021, 14, 2231-2242.	2.9	38
74	Current challenges for clinical trials of cardiovascular medical devices. International Journal of Cardiology, 2014, 175, 30-37.	1.7	37
75	Conceptual Considerations for Device-Based Therapy in Acute Decompensated Heart Failure. Circulation: Heart Failure, 2020, 13, e006731.	3.9	37
76	A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: Rationale, design, and baseline patient characteristics. American Heart Journal, 2008, 156, 641-648.e1.	2.7	36
77	Disease management: remote monitoring in heart failure patients with implantable defibrillators, resynchronization devices, and haemodynamic monitors. Europace, 2013, 15, i40-i46.	1.7	36
78	Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia. Kidney International, 2012, 82, 1215-1222.	5.2	35
79	Conduct of Clinical Trials in the Era of COVID-19. Journal of the American College of Cardiology, 2020, 76, 2368-2378.	2.8	35
80	Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With CardiacâResynchronization. JACC: Heart Failure, 2017, 5, 169-178.	4.1	34
81	Predictors of Clinical Response to Transcatheter Reduction of SecondaryâMitral Regurgitation. Journal of the American College of Cardiology, 2020, 76, 1007-1014.	2.8	34
82	Rationale and Design of the Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation (THE BALANCE) Study. Clinical and Translational Science, 2010, 3, 249-253.	3.1	33
83	Effect of Mitral Valve Gradient After MitraClip on Outcomes in Secondary Mitral Regurgitation. JACC: Cardiovascular Interventions, 2021, 14, 879-889.	2.9	32
84	Trials of implantable monitoring devices in heart failure: which design is optimal?. Nature Reviews Cardiology, 2014, 11, 576-585.	13.7	31
85	The Utility of a Wireless Implantable Hemodynamic Monitoring System in Patients Requiring Mechanical Circulatory Support. ASAIO Journal, 2018, 64, 301-308.	1.6	31
86	Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. Kidney International, 2012, 82, 1223-1230.	5.2	30
87	Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. American Journal of Cardiology, 2018, 121, 1400-1408.	1.6	30
88	A current and future outlook on upcoming technologies in remote monitoring of patients with heart failure. European Journal of Heart Failure, 2021, 23, 175-185.	7.1	30
89	Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes. Nature and Science of Sleep, 2021, Volume 13, 515-526.	2.7	30
90	Economic Value and Cost-Effectiveness ofâCardiac Resynchronization Therapy Among Patients With Mild Heart Failure. JACC: Heart Failure, 2017, 5, 204-212.	4.1	30

#	ARTICLE	IF	CITATIONS
91	A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First Ex-Vivo and Animal Experience. <i>Journal of Cardiovascular Translational Research</i> , 2019, 12, 290-298.	2.4	29
92	Design and rationale of haemodynamic guidance with CardioMEMS in patients with a left ventricular assist device: the HEMO-VAD pilot study. <i>ESC Heart Failure</i> , 2019, 6, 194-201.	3.1	29
93	Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 528-538.	7.1	28
94	Endpoints in Heart Failure Drug Development. <i>JACC: Heart Failure</i> , 2020, 8, 429-440.	4.1	28
95	Predictors of short-term clinical response to cardiac resynchronization therapy. <i>European Journal of Heart Failure</i> , 2017, 19, 1056-1063.	7.1	27
96	Baroreflex activation therapy for the treatment of heart failure with reduced ejection fraction in patients with and without coronary artery disease. <i>International Journal of Cardiology</i> , 2018, 266, 187-192.	1.7	27
97	First granted example of novel FDA trial design under Expedited Access Pathway for premarket approval: BeAT-HF. <i>American Heart Journal</i> , 2018, 204, 139-150.	2.7	27
98	Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. <i>American Heart Journal</i> , 2020, 219, 1-8.	2.7	27
99	Pulmonary Hypertension in Transcatheter Mitral Valve Repair for Secondary Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2595-2606.	2.8	27
100	Surgical Experience and Long-term Results of Baroreflex Activation Therapy for Heart Failure With Reduced Ejection Fraction. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2016, 28, 320-328.	0.6	26
101	Treatment of HF in an Era of Multiple Therapies. <i>JACC: Heart Failure</i> , 2021, 9, 1-12.	4.1	26
102	Patient monitoring across the spectrum of heart failure disease management 10 years after the CHAMPION trial. <i>ESC Heart Failure</i> , 2021, 8, 3472-3482.	3.1	26
103	Hemodynamic Factors Associated With Acute Decompensated Heart Failure: Part 2—Use in Automated Detection. <i>Journal of Cardiac Failure</i> , 2011, 17, 366-373.	1.7	25
104	<scp>d</scp>-Ribose aids heart failure patients with preserved ejection fraction and diastolic dysfunction: a pilot study. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2015, 9, 56-65.	2.1	25
105	Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease: Insights from a wireless pulmonary artery pressure monitoring system. <i>Journal of Heart and Lung Transplantation</i> , 2015, 34, 438-447.	0.6	24
106	Apneas of Heart Failure and Phenotype-Guided Treatments. <i>Chest</i> , 2020, 157, 394-402.	0.8	24
107	Health Status Changes and Outcomes in Patients With Heart Failure and Mitral Regurgitation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 2099-2106.	2.8	24
108	Design and rationale for the Stimulation Of the Left Ventricular Endocardium for Cardiac Resynchronization Therapy in non-responders and previously untreatable patients (SOLVE-CRT) trial. <i>American Heart Journal</i> , 2019, 217, 13-22.	2.7	23

#	ARTICLE	IF	CITATIONS
109	Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. <i>European Journal of Heart Failure</i> , 2020, 22, 2175-2186.	7.1	23
110	Prognostic implications of left ventricular global longitudinal strain in heart failure patients with narrow QRS complex treated with cardiac resynchronization therapy: a subanalysis of the randomized EchoCRT trial. <i>European Heart Journal</i> , 2017, 38, ehw506.	2.2	22
111	The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post- ∞ myocardial infarction heart failure: Trial rationale and study design. <i>American Heart Journal</i> , 2018, 201, 141-148.	2.7	22
112	Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population. <i>JACC: Heart Failure</i> , 2019, 7, 586-598.	4.1	22
113	Ambulatory Extra-Aortic Counterpulsation in Patients With Moderate to Severe Chronic Heart Failure. <i>JACC: Heart Failure</i> , 2014, 2, 526-533.	4.1	21
114	Current and future developments in the field of central sleep apnoea. <i>Europace</i> , 2016, 18, 1123-1134.	1.7	21
115	Optimal Background Pharmacological Therapy for Heart Failure Patients in Clinical Trials. <i>Journal of the American College of Cardiology</i> , 2022, 79, 504-510.	2.8	21
116	Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	20
117	Transcatheter Mitral Valve Repair in Patients With and Without Cardiac Resynchronization Therapy. <i>Circulation: Heart Failure</i> , 2020, 13, e007293.	3.9	20
118	Remote Hemodynamic-Guided Therapy of Patients With Recurrent Heart Failure Following Cardiac Resynchronization Therapy. <i>Journal of the American Heart Association</i> , 2021, 10, e017619.	3.7	20
119	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea: A Pooled Cohort Analysis. <i>Journal of Clinical Sleep Medicine</i> , 2019, 15, 1747-1755.	2.6	20
120	The V-LAP System for Remote Left Atrial Pressure Monitoring of Patients With Heart Failure. <i>Journal of Cardiac Failure</i> , 2022, 28, 963-972.	1.7	20
121	Pharmacologic Therapies Across the Continuum of Left Ventricular Dysfunction. <i>American Journal of Cardiology</i> , 2008, 102, 21G-28G.	1.6	19
122	Sex-Specific Outcomes of Transcatheter Mitral-Valve Repair and Medical Therapy for Mitral Regurgitation in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 674-683.	4.1	19
123	Preventing cardiovascular events in patients with diabetes mellitus. <i>American Journal of Medicine</i> , 2004, 116, 39-46.	1.5	18
124	The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (<sc>ATMOSPHERE</sc>): revised statistical analysis plan and baseline characteristics. <i>European Journal of Heart Failure</i> , 2015, 17, 1075-1083.	7.1	18
125	Aliskiren alone or in combination with enalapril vs. enalapril among patients with chronic heart failure with and without diabetes: a subgroup analysis from the <sc>ATMOSPHERE</sc> trial. <i>European Journal of Heart Failure</i> , 2018, 20, 136-147.	7.1	18
126	Defining a Clinically Important Change in 6-Minute Walk Distance in Patients With Heart Failure and Mitral Valve Disease. <i>Circulation: Heart Failure</i> , 2021, 14, e007564.	3.9	17

#	ARTICLE	IF	CITATIONS
127	Baseline Functional Capacity and Transcatheter Mitral Valve Repair in Heart Failure With Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2331-2341.	2.9	16
128	Optimizer Smart in the treatment of moderate-to-severe chronic heart failure. <i>Future Cardiology</i> , 2020, 16, 13-25.	1.2	16
129	Clinical and Hemodynamic Effects of Nesiritide (B-Type Natriuretic Peptide) in Patients With Decompensated Heart Failure Receiving β Blockers. <i>Congestive Heart Failure</i> , 2005, 11, 59-64.	2.0	15
130	Patient Perceptions on Facilitating Follow-Up After Heart Failure Hospitalization. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	15
131	Standardized Definitions for Evaluation of Heart Failure Therapies: Scientific Expert Panel From the Heart Failure Collaboratory and Academic Research Consortium. <i>JACC: Heart Failure</i> , 2020, 8, 961-972.	4.1	15
132	In-Hospital Management of Sleep Apnea During Heart Failure Hospitalization: A Randomized Controlled Trial. <i>Journal of Cardiac Failure</i> , 2020, 26, 705-712.	1.7	15
133	Remote Speech Analysis in the Evaluation of Hospitalized Patients With Acute Decompensated Heart Failure. <i>JACC: Heart Failure</i> , 2022, 10, 41-49.	4.1	15
134	Nesiritide in Acute Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials. <i>Clinical Cardiology</i> , 2010, 33, 484-489.	1.8	14
135	Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes. <i>Journal of the American College of Cardiology</i> , 2018, 71, 1325-1333.	2.8	14
136	Impact of COPD on Outcomes After MitraClip for Secondary Mitral Regurgitation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2795-2803.	2.9	14
137	Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM-HF and ATMOSPHERE. <i>European Journal of Heart Failure</i> , 2020, 22, 2370-2379.	7.1	14
138	Cardiac safety research consortium – shock II – think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. <i>American Heart Journal</i> , 2020, 230, 93-97.	2.7	14
139	Left Ventricular Global Longitudinal Strain as a Predictor of Outcomes in Patients with Heart Failure with Secondary Mitral Regurgitation: The COAPT Trial. <i>Journal of the American Society of Echocardiography</i> , 2021, 34, 955-965.	2.8	14
140	Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation. <i>Heart</i> , 2022, , heartjnl-2021-320005.	2.9	14
141	Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial. <i>European Heart Journal</i> , 2022, 43, 1639-1648.	2.2	14
142	Pilot Randomized Controlled Trial to Reduce Readmission for Heart Failure Using Novel Tablet and Nurse Practitioner Education. <i>American Journal of Medicine</i> , 2018, 131, 974-978.	1.5	13
143	Future research prioritization in cardiac resynchronization therapy. <i>American Heart Journal</i> , 2020, 223, 48-58.	2.7	13
144	Direct Interstitial Decongestion in an Animal Model of Acute-on-Chronic Ischemic Heart Failure. <i>JACC Basic To Translational Science</i> , 2021, 6, 872-881.	4.1	13

#	ARTICLE	IF	CITATIONS
145	Cardiac Resynchronization Therapy for the Management of Chronic Heart Failure. <i>The American Heart Hospital Journal</i> , 2003, 1, 55-61.	0.2	12
146	Response to Abraham. <i>Circulation</i> , 2006, 114, 2692-2698.	1.6	10
147	Long-Term Extrapolation of Clinical Benefits Among Patients With Mild Heart Failure Receiving Cardiac Resynchronization Therapy. <i>JACC: Heart Failure</i> , 2015, 3, 691-700.	4.1	10
148	Current treatment approaches and trials in central sleep apnea. <i>International Journal of Cardiology</i> , 2016, 206, S22-S27.	1.7	10
149	A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial. <i>American Heart Journal</i> , 2018, 199, 51-58.	2.7	9
150	Novel Non-pharmacological Approaches to Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 263-265.	2.4	8
151	Dose Response of β -Blockers in Adrenergic Receptor Polymorphism Genotypes. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002210.	3.6	8
152	Population Study of Urban, Rural, and Semiurban Regions for the Detection of Endovascular Disease and Prevalence of Risk Factors and Holistic Intervention Study: Rationale, Study Design, and Baseline Characteristics of PURSE-HIS. <i>Global Heart</i> , 2015, 10, 281.	2.3	8
153	Early Reduction in Ambulatory Pulmonary Artery Pressures After Initiation of Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2021, 14, e008212.	3.9	8
154	Prognostic Importance of Health Status Versus Functional Status in Heart Failure and Secondary Mitral Regurgitation. <i>JACC: Heart Failure</i> , 2021, 9, 684-692.	4.1	8
155	Age-Related Outcomes After Transcatheter Mitral Valve Repair in Patients With Heart Failure. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 397-407.	2.9	8
156	Cardiac resynchronization therapy: a review of clinical trials and criteria for identifying the appropriate patient. <i>Reviews in Cardiovascular Medicine</i> , 2003, 4 Suppl 2, S30-7.	1.4	8
157	Feasibility of remote speech analysis in evaluation of dynamic fluid overload in heart failure patients undergoing haemodialysis treatment. <i>ESC Heart Failure</i> , 2021, 8, 2467-2472.	3.1	7
158	Treatment of Anemia With Darbepoetin Alfa in Heart Failure. <i>Congestive Heart Failure</i> , 2010, 16, 87-95.	2.0	6
159	The Role of Implantable Hemodynamic Monitors to Manage Heart Failure. <i>Heart Failure Clinics</i> , 2015, 11, 183-189.	2.1	6
160	Design of a "Lean" Case Report Form for Heart Failure Therapeutic Development. <i>JACC: Heart Failure</i> , 2019, 7, 913-921.	4.1	6
161	Impact of Diabetes on Outcomes After Transcatheter Mitral Valve Repair in Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 559-567.	4.1	6
162	Optimization of Cardiac Resynchronization Devices Using Acoustic Cardiography: A Comparison to Echocardiography. <i>Congestive Heart Failure</i> , 2006, 12, 25-31.	2.0	5

#	ARTICLE	IF	CITATIONS
163	The Role of Implantable Hemodynamic Monitors to Manage Heart Failure. <i>Cardiology Clinics</i> , 2017, 35, 273-279.	2.2	5
164	Effect of cardiac resynchronization therapy in patients with diabetes randomized in <sc>EchoCRT</sc>. <i>European Journal of Heart Failure</i> , 2017, 19, 80-87.	7.1	5
165	Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. <i>Circulation</i> , 2021, 144, 1265-1267.	1.6	5
166	Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the <i>ADRB1</i> Arg389Arg Genotype. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2021, 14, e009591.	4.8	5
167	Switching to Evidence-Based Once-Daily β -Blockers for Improved Adherence to Medication Across the Continuum of Post-Myocardial Infarction Left Ventricular Dysfunction and Heart Failure. <i>Congestive Heart Failure</i> , 2008, 14, 272-280.	2.0	4
168	Interatrial shunting for the treatment of heart failure: an <sc>on-demand</sc>, <sc>self-regulating</sc> left atrial pressure lowering system. <i>European Journal of Heart Failure</i> , 2021, 23, 811-813.	7.1	4
169	Development and external validation of prognostic models to predict sudden and pump-failure death in patients with HFrEF from PARADIGM-HF and ATMOSPHERE. <i>Clinical Research in Cardiology</i> , 2021, 110, 1334-1349.	3.3	4
170	Pulmonary Artery Pressure Monitoring Effectively Guides Management to Reduce Heart Failure Hospitalizations in Obesity. <i>JACC: Heart Failure</i> , 2021, 9, 784-794.	4.1	4
171	Abstract 16744: Impact of Wireless Pulmonary Artery Pressure Monitoring on Heart Failure Hospitalizations and All-Cause 30-Day Readmissions in Medicare-Eligible Patients With NYHA Class III Heart Failure: Results From the CHAMPION Trial. <i>Circulation</i> , 2014, 130, .	1.6	4
172	Remote Heart Failure Monitoring. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2013, 15, 556-564.	0.9	3
173	The Use of MitraClip in Secondary Mitral Regurgitation and Heart Failure. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1606-1612.	0.8	3
174	Wireless Hemodynamic Monitoring in Patients with Heart Failure. <i>Current Heart Failure Reports</i> , 2021, 18, 12-22.	3.3	3
175	Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials. <i>American Heart Journal</i> , 2021, 237, 45-53.	2.7	3
176	Cardiac computed tomography assessment of the near term impact of percutaneous ventricular restoration therapy (parachute ^Å) on mitral valve geometry. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, E45-51.	1.7	2
177	Phrenic nerve stimulation in patients with central sleep apnea: a single-center experience from pilot and pivotal trials evaluating the remed ^Å System. <i>Kardiologia Polska</i> , 2019, 77, 553-560.	0.6	2
178	Cardiac Resynchronization Therapy in Heart Failure. <i>Annals of Internal Medicine</i> , 2005, 142, 307.	3.9	1
179	Evaluating the quality of implantation of percutaneous ventricular restoration device (Parachute ^Å) by cardiac computed tomography. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E104-E111.	1.7	1
180	The Davis Heart and Lung Research Institute. <i>Circulation Research</i> , 2017, 120, 1068-1071.	4.5	1

#	ARTICLE	IF	CITATIONS
181	Comprehensive Pharmacologic Management Strategies for Heart Failure. , 0, , 15-34.		1
182	Who and when to clip: that is the question. European Journal of Heart Failure, 2020, 22, 20-22.	7.1	1
183	Diabetes, hypertension, and renal insufficiency in post-myocardial infarction cardiovascular risk. Reviews in Cardiovascular Medicine, 2003, 4 Suppl 3, S30-6.	1.4	1
184	Imaging Device Therapy. Heart Failure Clinics, 2019, 15, 305-320.	2.1	0
185	Abstract 215: Principal Components Analysis in a South Asian Population: Cardiovascular Risk Variable Clustering and Obesity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, .	2.4	0
186	Abstract 16318: Clinical and Economic Value of Maximizing Response to Cardiac Resynchronization Therapy (CRT): Evidence From 5 Randomized Controlled Trials. Circulation, 2014, 130, .	1.6	0
187	Dose Limiting, Adverse Event Associated Bradycardia with β -blocker Treatment of Atrial Fibrillation in the GENETIC-AF Trial. Heart Rhythm O2, 2021, 3, 40-49.	1.7	0
188	Practical considerations for switching beta-blockers in heart failure patients. Reviews in Cardiovascular Medicine, 2004, 5 Suppl 1, S36-44.	1.4	0
189	Clinical Trials Supporting Current Indications for CRT. , 0, , 261-276.		0
190	Abstract 15860: Arterial and Cardiac Hemodynamics in Advanced HF Patients Implanted With the C-Pulse Counterpulsation Device: Implications for Myocardial Recovery. Circulation, 2015, 132, .	1.6	0
191	Abstract 19802: Implantable Hemodynamic Monitoring Reduces Heart Failure Hospitalizations Due to Congestion Regardless of Perfusion Status. Circulation, 2015, 132, .	1.6	0